# Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab (AMG 162) in Japanese Postmenopausal Women

> **NCT03822078** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 45 (actual)

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** Placebo
- **BIOLOGICAL:** Denosumab

## Key facts

- **NCT ID:** NCT03822078
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09-30
- **Primary completion:** 2004-12-24
- **Final completion:** 2004-12-24
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2019-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03822078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03822078, "Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab (AMG 162) in Japanese Postmenopausal Women". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03822078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*